Don't qualify for this program? Visit the DBAs to look for financial assistance based on your diagnosis.  
 

The Free Drug Program

This program provides medication at no cost.

Provided by: Biogen

5000 Davis Drive
PO Box 13919
Research Triangle Park
Morrisville, NC 27709

TEL: 800-456-2255


Languages Spoken:

English

Program Website

 

Patient Assistance Applications

The Free Drug Program: Contact program

 

Brand Name Medications Covered

 
  • Avonex injection
  • Tysabri vial; single-use
  • Plegridy injection
  • Zinbryta
  • Tecfidera capsule; delayed release
 

Generic Name

 
  • daclizumab
  • natalizumab vial; single-use
  • dimethyl fumarate capsule; delayed release
  • peginterferon beta-1a injection
  • interferon beta-1a injection
 

Eligibility Requirements   

Insurance Status Must be uninsured or underinsured
Those with Part D Eligible? Yes
Income Not disclosed
Diagnosis/Medical Criteria Relapsing form of MS
US Residency Required? Must reside in the US
   

Application

Obtaining Applicant must call for prescreening
Receiving There is no application
Returning Not specified
Doctor's Action Fax in prescription
Applicant's Action Provide information and proof of income
Decision Communicated Decision made during phone screening
Decision Timeframe Not specified
   

Medication

Amount/Supply Not specified
Sent To Not applicable
Delivery Time Not specified
Refill Process Company contacts patient to arrange
Limit None
Re-application Company contacts patient about reapplying
   

Additional Information

Patients will be referred to a financial assistance counselor. Decisions made on a case by case basis. Program assistance can range from a temporary need up to a 1 year enrollment period. For Avonex, Tecfidera and Plegridy: up to a 90-day supply is sent to the doctor's office or the patient's home. For Tysabri: a one month supply is sent to the doctor's office or site of care for administration of the infusion.

Insurance benefits, claims assistance and/or other reimbursement help is offered.


Updated July 17, 2017